Department of Surgery, Athens Naval and Veterans Hospital, 70 Deinokratous Str, Athens, Greece.
Department of ENT Surgery, Athens Naval and Veterans Hospital, Athens, Greece.
Hormones (Athens). 2019 Sep;18(3):289-295. doi: 10.1007/s42000-019-00119-3. Epub 2019 Jul 10.
The biologic and clinical significance of reactive C cell hyperplasia (CCH), adjacent to differentiated thyroid cancers, remains unknown. Our aim was to investigate the presence of CCH in thyroidectomy specimens with papillary thyroid carcinomas (PTC) and discuss its epidemiology and histology. In total, 413 patients were prospectively included in the study (189 benign goiters, 224 PTC). Reactive CCH was observed in 9.8% of PTC cases (32% males, 68% females, mean age 48.3 ± 16.4 years) and usually ipsilateral to the primary tumor (91%). Histologically, CCH was either focal (91%) or diffuse (9%) and almost always (92%) found in the middle or upper thirds of the thyroid lobes. Patients with PTC/CCH were generally younger than patients with benign goiters (0.027). On the other hand, patients with PTC and with PTC/CCH did not differ in terms of age, gender, basal calcitonin levels, primary tumor size, multifocality, extrathyroidal invasion, or lymph node metastasis. Thyroiditis, however, was more frequent in cases with PTC/CCH compared to PTC alone. Reactive CCH is considered a physiological response of the C cells to various stimuli, differentiated thyroid cancer among others. It bears no malignant potential and requires no additional treatment, following thyroidectomy.
反应性 C 细胞增生(CCH)紧邻分化型甲状腺癌,其生物学和临床意义尚不清楚。我们的目的是研究伴有甲状腺乳头状癌(PTC)的甲状腺切除术标本中 CCH 的存在情况,并讨论其流行病学和组织学特征。共有 413 例患者前瞻性纳入研究(良性甲状腺肿 189 例,PTC 224 例)。PTC 病例中观察到反应性 CCH 占 9.8%(男性占 32%,女性占 68%,平均年龄 48.3±16.4 岁),且通常与原发性肿瘤同侧(91%)。组织学上,CCH 为局灶性(91%)或弥漫性(9%),几乎总是(92%)位于甲状腺叶的中或上三分之一。伴有 PTC/CCH 的患者通常比伴有良性甲状腺肿的患者年轻(0.027)。另一方面,伴有 PTC 和伴有 PTC/CCH 的患者在年龄、性别、基础降钙素水平、原发肿瘤大小、多灶性、甲状腺外侵犯或淋巴结转移方面无差异。然而,与单纯 PTC 相比,伴有 PTC/CCH 的病例中更常出现甲状腺炎。反应性 CCH 被认为是 C 细胞对各种刺激(包括分化型甲状腺癌)的生理反应。它没有恶性潜能,在甲状腺切除术后无需额外治疗。